NYSE:ZYME (Zymeworks Inc.)
About ZYME
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its lead clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Zymeworks Inc. (NYSE: ZYME) Latest News
Investing
3 Hot Stocks to Buy in October
Tech Stocks
These Were the Worst-Performing Stocks on the TSX Last Week
Investing
3 Top TSX Stocks for the Future
Stocks for Beginners
3 Top Canadian Pharma Stocks for Ambitious Investors
Top TSX Stocks
3 BioPharm Stocks Yielding 100% Yearly Returns
Dividend Stocks
3 Top Canadian Healthcare Stocks for Growth Investors
Investing
This 2017 IPO Still Boasts Massive Growth Potential
Investing
Alert! 2 High-Growth Stocks to Buy Before 2020
Investing
Top 2 TSX Healthcare Stocks to Buy in June
Investing
This High-Growth Biopharma Stock Just Got Some Great News
Cannabis Stocks
2 High-Growth Stocks That Could Explode in the Next Decade
Investing
2 Stocks That Can Make You a TFSA Millionaire
1❯